Seth Egan - Co Diagnostics Chief Officer
| CODX Stock | USD 0.74 0.01 0.77% |
Executive
Seth Egan is Chief Officer of Co Diagnostics
| Address | 2401 South Foothill Drive, Salt Lake City, UT, United States, 84109 |
| Phone | (801) 438-1036 |
| Web | https://www.codiagnostics.com |
Co Diagnostics Management Efficiency
The company has return on total asset (ROA) of (0.2761) % which means that it has lost $0.2761 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5057) %, meaning that it created substantial loss on money invested by shareholders. Co Diagnostics' management efficiency ratios could be used to measure how well Co Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2024. Return On Capital Employed is likely to rise to -0.45 in 2024. At this time, Co Diagnostics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 34.8 M in 2024, whereas Total Assets are likely to drop slightly above 50.6 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Amir Rippel | NanoVibronix | N/A | |
| Kelley Nicholas | Neuropace | N/A | |
| Michael Soule | Movano Inc | N/A | |
| Stephanie Huebner | Vivos Therapeutics | N/A | |
| Thomas Stankovich | ReShape Lifesciences | 63 | |
| Paul Pignato | CVRx Inc | N/A | |
| Jennifer Englund | CVRx Inc | N/A | |
| MSc MD | CVRx Inc | N/A | |
| Adrien Mithalal | Inogen Inc | N/A | |
| Al Diaz | ReShape Lifesciences | N/A | |
| Leah Akin | Neuropace | N/A | |
| Jeremy Stigall | Clearpoint Neuro | 40 | |
| Grgoire Ramade | Inogen Inc | 54 | |
| Sean CPA | Rapid Micro Biosystems | 55 | |
| Lisa Wolf | Tivic Health Systems | 61 | |
| Jacqueline Keller | Clearpoint Neuro | N/A | |
| Amy Treadwell | Neuropace | N/A | |
| Kimberly Bambach | Tivic Health Systems | 53 | |
| Dylan John | Neuropace | N/A | |
| MBA MD | Inogen Inc | 51 | |
| Michael Wysocki | Rapid Micro Biosystems | N/A | |
Management Performance
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.28 |
Co Diagnostics Leadership Team
Elected by the shareholders, the Co Diagnostics' board of directors comprises two types of representatives: Co Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CODX. The board's role is to monitor Co Diagnostics' management team and ensure that shareholders' interests are well served. Co Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Co Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Thurston, Chief Officer | ||
| Andrew Benson, Head Relations | ||
| Brian CPA, CFO Secretary | ||
| Mayuranki Almaula, Senior Alliances | ||
| Dan CPA, Vice Accounting | ||
| Reed Benson, CFO, Secretary | ||
| Ivory Chang, Chief Officer | ||
| David Nielsen, Chief Officer | ||
| Cameron Gundry, Head LATAMEUR | ||
| Brent Satterfield, Chief Science Officer, Director | ||
| Dwight Egan, Chairman of the Board and Presidentident, CEO | ||
| Richard Abbott, President | ||
| Seth Egan, Chief Officer | ||
| Mark Poritz, Chief Officer |
CODX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Co Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (15.96) % | ||||
| Current Valuation | (11.99 M) | ||||
| Shares Outstanding | 31.93 M | ||||
| Shares Owned By Insiders | 6.70 % | ||||
| Shares Owned By Institutions | 13.95 % | ||||
| Number Of Shares Shorted | 228.28 K | ||||
| Price To Earning | 6.78 X | ||||
| Price To Book | 0.37 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CODX Stock Analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.